Document Detail


A randomised controlled trial of stress reduction for hypertension in older African Americans.
MedLine Citation:
PMID:  7591024     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We tested the short-term efficacy and feasibility of two stress education approaches toe the treatment of mild hypertension in older African Americans. This was a randomized, controlled, single-blind trial with 3 months of follow-up in primary care, inner-city health center. Of 213 African American men and women screened, 127 individuals (aged 55 to 85 years with initial diastolic pressure of 90 to 109 mm Hg, systolic pressure of < or = 189 mm Hg, and final baseline blood pressure of < or = 179/104 mm Hg) were selected. Of these, 16 did not complete follow-up blood pressure measurements. Mental and physical stress reduction approaches (Transcendental Meditation and progressive muscle relaxation) were compared with a lifestyle modification education control program and with each other. The primary outcome measures were changes in clinic diastolic and systolic pressures from baseline to final follow-up, measured by blinded observers. The secondary measures were linear blood pressure trends, changes in home blood pressure, and intervention compliance. Adjusted for significant baseline differences and compared with control, Transcendental Meditation reduced systolic pressure by 10.7 mm Hg (P < .0003) and diastolic pressure by 6.4 mm Hg (P <.00005). Progressive muscle relaxation lowered systolic pressure by 4.7 mm Hg (P = 0054) and diastolic pressure by 3.3 mm Hg (P <.02). The reductions in the Transcendental Meditation group were significantly greater than in the progressive muscle relaxation group for both systolic blood pressure (P = .02) and diastolic blood pressure (P = .03). Linear trend analysis confirmed these patterns.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
R H Schneider; F Staggers; C N Alxander; W Sheppard; M Rainforth; K Kondwani; S Smith; C G King
Related Documents :
2188824 - Angiotensin-converting enzyme (ace) inhibition. therapeutic option for diabetic hyperte...
2064494 - The treatment of mild hypertension study. a randomized, placebo-controlled trial of a n...
20827284 - Effects of fluvastatin on insulin resistance and cardiac morphology in hypertensive pat...
22124434 - Sex differences in the pressor and tubuloglomerular feedback response to angiotensin ii.
8246814 - Lymphatic capillary pressure in patients with primary lymphedema.
25121754 - Assessment of the relationship between nondipping phenomenon and microvolt t-wave alter...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Hypertension     Volume:  26     ISSN:  0194-911X     ISO Abbreviation:  Hypertension     Publication Date:  1995 Nov 
Date Detail:
Created Date:  1995-12-07     Completed Date:  1995-12-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  820-7     Citation Subset:  IM    
Affiliation:
Department of Physiological and Biological Sciences, Maharishi University of Management, Fairfield, Iowa 52557-1028, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
African Americans*
African Continental Ancestry Group
Aged
Aged, 80 and over
Female
Follow-Up Studies
Humans
Hypertension / etiology,  psychology,  therapy*
Male
Meditation*
Middle Aged
Patient Compliance
Patient Education as Topic*
Single-Blind Method
Stress, Psychological / complications,  psychology,  therapy*
Grant Support
ID/Acronym/Agency:
5R01HL-48107/HL/NHLBI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Contribution of atrial reservoir function to ventricular filling in hypertensive patients. Effects o...
Next Document:  Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism.